Barthélemy et al. [225] reported that CSF tau phosphorylated at Threonine 217 (p-T217) is specifically associated with amyloid-β pathology, suggesting a strong interplay between AD amyloidosis and hyperphosphorylation of tau on p-T217; moreover, p-T217 outperforms p-T181 as a biomarker for detecting both the preclinical and advanced forms of Alzheimer’s disease. Here, MAPT is linked to Alzheimer disease.